News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
APOXIS S.A. Receives FDA Orphan Medicinal Product Designation For APO200 For The Treatment Of XLHED
February 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Apoxis SA, a Swiss biopharmaceutical company developing oncology and immunology products, today announced it has received Orphan Medicinal Product designation from the FDA for its rare disease protein therapeutic, APO200.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ROSE BIOSOLUTIONS
Successful CDMO partnerships hinge on honest—and sometimes critical—support
October 12, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Drug Development
Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
October 8, 2026
·
2 min read
·
Gabrielle Masson
Insights
Beyond equity: Why venture debt is reshaping European biotech
October 8, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Opinion
FDA must ensure American patients can access new and experimental drugs
October 5, 2026
·
7 min read
·
Houman David Hemmati
